A Pilot Study of Xifaxan to Treat Patients With PSC
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
In the current protocol, we propose the assessment of potential beneficial effects of the
antibiotic Xifaxan on liver biochemistries, liver related symptoms and Mayo risk score in 15
adult and 5 pediatric patients with PSC. Adult patients will receive Xifaxan, 550 mg twice
daily over a 12-week period. Pediatric patients with PSC whose weight is greater than or
equal to 40 kg will receive Xifaxan, 550 mg twice daily.